KN044 / Alphamab - LARVOL DELTA

KN044 - Asia: an AMR hot zone (ESCMID Global 2025) - "This keynote lecture will give an overview of AMR in ASIA and review the results of the epidemiological study ACORN-HAI. Additionally, it will explore strategies for developing clinical trial capacity in many low- and middle-income countries in Asia and why this is vital in combating AMR in the long term."

Infectious Disease

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD | Trial completion date: Aug 2023 ➔ Aug 2024 | Trial primary completion date: Jun 2023 ➔ Jun 2024

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=39 | Recruiting | Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD | Trial completion date: Aug 2022 ➔ Aug 2023 | Trial primary completion date: Jun 2022 ➔ Jun 2023

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=39; Recruiting; Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD; Trial completion date: Dec 2021 ➔ Aug 2022; Trial primary completion date: Sep 2021 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=39; Recruiting; Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=39; Not yet recruiting; Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD

Clinical • New P1 trial